Genetic Research of Monogenic Obesity in a Pediatric Cohort With Severe and Early Onset Obesity

University Hospital, Bordeaux1 site in 1 country100 target enrollmentOctober 1, 2022

ConditionsMonogenic Obesity

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Monogenic Obesity
Sponsor: University Hospital, Bordeaux
Enrollment: 100
Locations: 1
Primary Endpoint: Positivity rate of patients for whom a diagnosis of monogenic obesity will be obtained when all analyses have been performed.
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Obesity is a frequent disease mainly caused by environmental/polygenic factors and more rarely caused by the alteration of a single gene ("monogenic obesity"). The diagnosis of these rare forms can lead to personalized management (new treatments, prognosis, adapted hygienic and dietary rules) and family screening. The use of a panel covering the known causes of monogenic obesity on a pediatric cohort of severe and early obesity will allow to evaluate the relevance of these analyses to adapt the management of this type of patients.

Registry

clinicaltrials.gov

Start Date

October 1, 2022

End Date

January 1, 2024

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

University Hospital, Bordeaux

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Recruitment age: 2-17 years
•Body mass index, greater than the International Obesity Task Force (IOTF) 30 curve before the age of 5
•Care at the specialized pediatric obesity center (CSO) of the Bordeaux University Hospital
•Informed consent signed

Exclusion Criteria

•no informed consent

Outcomes

Primary Outcomes

Positivity rate of patients for whom a diagnosis of monogenic obesity will be obtained when all analyses have been performed.

Time Frame: Inclusion visit

Secondary Outcomes

Number of patients for whom a genetic finding will have changed management and description of changes.(Inclusion visit)
Number of Patients eligible for a drug targeting single-gene obesity(Inclusion visit)